# Correlation Between Intravascular Platelet Aggregation in Tumors and Hypoxia-Inducible Factor 1 Alpha Expression in Epithelial Ovarian Cancer: Implications for Prognosis and Staging

## TL;DR

This study finds that platelet aggregation in ovarian tumors is linked to hypoxia and worse patient outcomes, suggesting a new factor in cancer progression and prognosis.

## Contribution

The study identifies a novel link between intravascular platelet aggregation and hypoxia-inducible factor 1 alpha (HIF-1α) in epithelial ovarian cancer prognosis.

## Key findings

- Intravascular platelet aggregation correlates with advanced stages and poor prognosis in ovarian cancer.
- Platelet aggregation is associated with increased HIF-1α expression, indicating hypoxia involvement.
- Higher platelet aggregation grades are statistically significant predictors of worse survival outcomes.

## Abstract

This study investigates the association between intravascular platelet aggregation in tumors and the prognosis of patients with ovarian cancer, which is often diagnosed at an advanced stage. The findings suggest that intravascular platelet aggregation in tumors contributes to the formation of a hypoxic environment, which in turn promotes cancer progression, metastasis, and resistance to treatment, leading to poorer survival outcomes. This research has the potential to influence future approaches to managing ovarian carcinoma and improving patient outcomes.

Background/Objectives: This study aimed to evaluate the association between intravascular platelet aggregation in tumors and ovarian carcinoma prognosis and investigate underlying mechanisms. Methods: A retrospective analysis was conducted on 144 patients with ovarian carcinoma. Immunohistochemical staining for CD42b, hypoxia-inducible factor-1α (HIF-1α), platelet-derived growth factor (PDGF), and vascular endothelial growth factor (VEGF) was performed using tissue microarrays to assess intravascular platelet aggregation. Staining grades ranged from 1 to 3 for CD42b (platelet aggregation or microthrombus) and 0 to 3 for HIF-1α, PDGF, and VEGF. Results: Among the patients, 25 (17.4%) had grade 1 (no platelet aggregation), 85 (59.0%) had grade 2 (platelet aggregation), and 34 (23.6%) had grade 3 (microthrombus). The grade of intravascular platelet aggregation in ovarian carcinoma was statistically significantly associated with a poor prognosis (p = 0.037). In addition, in patients with more advanced stages of ovarian cancer, higher levels of intravascular platelet aggregation were observed. Additional analysis revealed a correlation between platelet aggregation and HIF-1α expression (correlation coefficient = 0.226, p= 0.006), while PDGF and VEGF showed no significant correlations. Conclusions: Intravascular platelet aggregation in tumors is associated with advanced stages and poor prognosis in ovarian carcinoma. The results of our study suggest a potential association with hypoxia induced by intravascular platelet aggregation in ovarian carcinoma.